ProCE Banner Activity

Phase I/II Trial of Quizartinib, Venetoclax, and Decitabine in FLT3-ITD–Mutated AML

Conference Coverage

The combination of quizartinib, venetoclax, and decitabine demonstrated clinical activity in patients with newly diagnosed and relapsed/refractory FLT3-ITD–mutated AML with manageable toxicity.

Released: December 12, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.